A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure
Chien, Kelly Sharon, Rodriguez-Sevilla, Juan Jose, Alvarado Valero, Yesid, Bravo, Guillermo Montalban, Hammond, Danielle, Swaminathan, Mahesh, Bazinet, Alexandre, Kimberley, Jacqueline, Bodden, Kristy, Schneider, Heather, Dong, Xiao Qin, Pierce, Sherry, Huang, Xuelin, Jabbour, Elias, Kantarjian, Hagop M., Garcia-Manero, Guillermo
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure
Chien, Kelly S., Rodriguez-Sevilla, Juan Jose, Alvarado, Yesid, Montalban-Bravo, Guillermo, Hammond, Danielle E., Swaminathan, Mahesh, Bazinet, Alexandre, Kimberley, Jacqueline, Bodden, Kristy, Schneider, Heather, Dong, Xiao Qin, Pierce, Sherry A., Huang, Xuelin, Jabbour, Elias J., Kantarjian, Hagop M., Garcia-Manero, Guillermo
Published in Leukemia research (01.12.2024)
Published in Leukemia research (01.12.2024)
Get full text
Journal Article
MDS-537 A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients With Myelodysplastic Syndromes After Hypomethylating Agent (HMA) Failure
Chien, Kelly, Jose Rodriguez-Sevilla, Juan, Alvarado, Yesid, Montalban-Bravo, Guillermo, Hammond, Danielle E., Swaminathan, Mahesh, Bazinet, Alexandre, Kimberley, Jacqueline, Bodden, Kristy, Schneider, Heather, Huang, Xuelin, Jabbour, Elias J., Kantarjian, Hagop M., Garcia-Manero, Guillermo
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Get full text
Journal Article
A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients With Myelodysplastic Syndromes After Hypomethylating Agent (HMA) Failure
Chien, Kelly, Jose Rodriguez-Sevilla, Juan, Alvarado, Yesid, Montalban-Bravo, Guillermo, Hammond, Danielle E., Swaminathan, Mahesh, Bazinet, Alexandre, Kimberley, Jacqueline, Bodden, Kristy, Schneider, Heather, Huang, Xuelin, Jabbour, Elias J., Kantarjian, Hagop M., Garcia-Manero, Guillermo
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Get full text
Journal Article
Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)
Morita, Kiyomi, Montalban Bravo, Guillermo, Sasaki, Koji, Bodden, Kristy R., Wang, Feng, Bose, Prithviraj, Alvarado, Yesid, Daver, Naval, Borthakur, Gautam, Ravandi, Farhad, Takahashi, Koichi, Jabbour, Elias, DiNardo, Courtney D., Pemmaraju, Naveen, Kadia, Tapan M., Ohanian, Maro, Pierce, Sherry A., Azab, Mohammad, Kantarjian, Hagop M., Garcia-Manero, Guillermo
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure
Swaminathan, Mahesh, Borthakur, Gautam, Kadia, Tapan M., Ferrajoli, Alessandra, Alvarado, Yesid, Pemmaraju, Naveen, Bodden, Kristy, Yearby, Brittany, Konopleva, Marina, Khoury, Joseph, Bueso-Ramos, Carlos, Garcia-Manero, Guillermo, DiNardo, Courtney D.
Published in Leukemia & lymphoma (29.07.2019)
Published in Leukemia & lymphoma (29.07.2019)
Get full text
Journal Article
Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)
Garcia-Manero, Guillermo, Sasaki, Koji, Montalban-Bravo, Guillermo, Bodden, Kristy R., Bose, Prithviraj, Alvarado, Yesid, Daver, Naval G., Borthakur, Gautam, Ravandi, Farhad, Takahashi, Koichi, Cortes, Jorge E., Jabbour, Elias J., Naqvi, Kiran, DiNardo, Courtney D., Benton, Christopher B., Pemmaraju, Naveen, Kadia, Tapan M., Ohanian, Maro N., Pierce, Sherry A., Kantarjian, Hagop M.
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article
Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial
Khan, Maliha, Kristy, Bodden, Kadia, Tapan, Ferrajoli, Alessandra, Alvarado, Yesid, Borthakur, Gautam, Pemmaraju, Naveen, Konopleva, Marina, Garcia-Manero, Guillermo, DiNardo, Courtney
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article
Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia
Montalban-Bravo, Guillermo, Bose, Prithviraj, Alvarado, Yesid, Daver, Naval Guastad, Ravandi, Farhad, Borthakur, Gautam, Takahashi, Koichi, Andreeff, Michael, Cortes, Jorge E., Dinardo, Courtney Denton, Jabbour, Elias, Kadia, Tapan M., Kornblau, Steven, Ohanian, Maro, Huang, Xuelin, Nogueras-Gonzalez, Graciela M., Bodden, Kristy, Pierce, Sherry, Kantarjian, Hagop M., Garcia-Manero, Guillermo
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Montalban-Bravo, Guillermo, Bose, Prithviraj, Alvarado, Yesid, Daver, Naval, Ravandi, Farhad, Borthakur, Gautam, Takahashi, Koichi, Andreeff, Michael, Cortes, Jorge E., DiNardo, Courtney D., Jabbour, Elias, Kadia, Tapan M., Kornblau, Steven M., Ohanian, Maro, Alfonso Pierola, Ana, Huang, Xuelin, Nogueras-Gonzalez, Graciela M., Bodden, Kristy, Littles, Kristina, Pierce, Sherry, Bueso-Ramos, Carlos E, Kantarjian, Hagop M., Garcia-Manero, Guillermo
Published in Blood (02.12.2016)
Published in Blood (02.12.2016)
Get full text
Journal Article
Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML
Urrutia, Samuel, Bose, Prithviraj, Alvarado, Yesid, Borthakur, Gautam, Ravandi, Farhad, Daver, Naval, Pemmaraju, Naveen, Jabbour, Elias, Takahashi, Koichi, Kadia, Tapan, DiNardo, Courtney, Kornblau, Steven, Kanagal-Shamanna, Rashmi, Huang, Xuelin, Bodden, Kristy, Kantarjian, Hagop, Garcia-Manero, Guillermo
Published in Blood Neoplasia (01.06.2024)
Published in Blood Neoplasia (01.06.2024)
Get full text
Journal Article